Predicting effect of food on extent of drug absorption based on physicochemical properties
- PMID: 17385020
- DOI: 10.1007/s11095-007-9236-1
Predicting effect of food on extent of drug absorption based on physicochemical properties
Erratum in
- Pharm Res. 2008 Apr;25(4):979
Abstract
Purpose: To develop a statistical model for predicting effect of food on the extent of absorption (area under the curve of time-plasma concentration profile, AUC) of drugs based on physicochemical properties.
Materials and methods: Logistic regression was applied to establish the relationship between the effect of food (positive, negative or no effect) on AUC of 92 entries and physicochemical parameters, including clinical doses used in the food effect study, solubility (pH 7), dose number (dose/solubility at pH 7), calculated Log D (pH 7), polar surface area, total surface area, percent polar surface area, number of hydrogen bond donor, number of hydrogen bond acceptors, and maximum absorbable dose (MAD).
Results: For compounds with MAD >or= clinical dose, the food effect can be predicted from the dose number category and Log D category, while for compounds with MAD < clinical dose, the food effect can be predicted from the dose number category alone. With cross validation, 74 out of 92 entries (80%) were predicted into the correct category. The correct predictions were 97, 79 and 68% for compounds with positive, negative and no food effect, respectively.
Conclusions: A logistic regression model based on dose, solubility, and permeability of compounds is developed to predict the food effect on AUC. Statistically, solubilization effect of food primarily accounted for the positive food effect on absorption while interference of food with absorption caused negative effect on absorption of compounds that are highly hydrophilic and probably with narrow window of absorption.
Similar articles
-
In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.Eur J Pharm Sci. 2013 Jul 16;49(4):679-98. doi: 10.1016/j.ejps.2013.05.019. Epub 2013 May 29. Eur J Pharm Sci. 2013. PMID: 23727464
-
The effect of food on the absorption and pharmacokinetics of rivaroxaban.Int J Clin Pharmacol Ther. 2013 Jul;51(7):549-61. doi: 10.5414/CP201812. Int J Clin Pharmacol Ther. 2013. PMID: 23458226 Clinical Trial.
-
Food, gastrointestinal pH, and models of oral drug absorption.Eur J Pharm Biopharm. 2017 Mar;112:234-248. doi: 10.1016/j.ejpb.2016.11.034. Epub 2016 Nov 30. Eur J Pharm Biopharm. 2017. PMID: 27914234 Review.
-
Investigation of some factors contributing to negative food effects.Biopharm Drug Dispos. 2009 Mar;30(2):71-80. doi: 10.1002/bdd.647. Biopharm Drug Dispos. 2009. PMID: 19226652
-
Integrating drug permeability with dissolution profile to develop IVIVC.Biopharm Drug Dispos. 2012 Oct;33(7):354-65. doi: 10.1002/bdd.1792. Epub 2012 Jun 7. Biopharm Drug Dispos. 2012. PMID: 22581486 Review.
Cited by
-
Use of Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Drug-Food Interactions: an Industry Perspective.AAPS J. 2020 Sep 27;22(6):123. doi: 10.1208/s12248-020-00508-2. AAPS J. 2020. PMID: 32981010 Free PMC article.
-
Prediction of Oral Drug Absorption in Rats from In Vitro Data.Pharm Res. 2023 Feb;40(2):359-373. doi: 10.1007/s11095-022-03173-6. Epub 2022 Feb 15. Pharm Res. 2023. PMID: 35169960
-
Bridging population pharmacokinetic and semimechanistic absorption modeling of APX3330.CPT Pharmacometrics Syst Pharmacol. 2024 Jan;13(1):106-117. doi: 10.1002/psp4.13061. Epub 2023 Oct 26. CPT Pharmacometrics Syst Pharmacol. 2024. PMID: 37884051 Free PMC article.
-
Fixed-dose combination orally disintegrating tablets to treat cardiovascular disease: formulation, in vitro characterization and physiologically based pharmacokinetic modeling to assess bioavailability.Drug Des Devel Ther. 2017 Mar 16;11:811-826. doi: 10.2147/DDDT.S126035. eCollection 2017. Drug Des Devel Ther. 2017. PMID: 28352156 Free PMC article. Clinical Trial.
-
Pharmacokinetics and pharmacodynamics of single-dose oral tolvaptan in fasted and non-fasted states in healthy Caucasian and Japanese male subjects.Eur J Clin Pharmacol. 2012 Dec;68(12):1595-603. doi: 10.1007/s00228-012-1295-5. Epub 2012 May 15. Eur J Clin Pharmacol. 2012. PMID: 22585285 Clinical Trial.
References
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources